Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Single Arm, Phase 2 Trial of Pembrolizumab in Treatment Naïve Patients With Poor-Prognosis Carcinoma of Unknown Primary Site

NCT03391973 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.

NCT NCT03391973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03391973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Single Arm, Phase 2 Trial of Pembrolizumab in Treatment Naïve Patients With Poor-Prognosis Carcinoma of Unknown Primary Site
Lead sponsor
AHS Cancer Control Alberta
Phase
Phase 2
Overall status
Completed
Start date
August 24, 2018
Completion date
February 12, 2026
Enrollment
33 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma of unknown primary